Biocon Limited has announced the full integration of its material subsidiary, Biocon Biologics Limited (BBL), as a wholly-owned subsidiary. The company reported strong financial results for the quarter ended March 31, 2026, while also announcing a final dividend of Re. 0.50 per share. Additionally, the Board has approved key leadership appointments, a new long-term incentive plan, and strategic acquisitions of remaining equity shares in BBL to simplify corporate structure.
Financial Performance Overview
For the quarter ended March 31, 2026, Biocon Limited reported standalone revenue from operations of Rs. 6,047 million, with a net profit of Rs. 510 million. On a consolidated basis, the company achieved total income of Rs. 1,72,695 million for the full financial year 2026. The Board of Directors has recommended a final dividend of 10%, amounting to Re. 0.50 per equity share, payable by August 31, 2026, following approval at the upcoming Annual General Meeting scheduled for August 06, 2026.
Strategic Integration and Acquisitions
The company is moving toward full integration of Biocon Biologics Limited (BBL) to establish a unified global biopharmaceutical leader. To facilitate this, the Board approved the acquisition of remaining equity shares in BBL held by employees and other shareholders through a preferential issue of up to 87,92,317 equity shares of Biocon Limited at an issue price of Rs. 376.16 per share. This share swap is designed to simplify the corporate structure, enable a unified capital allocation strategy, and drive operational synergies.
Leadership Changes and Governance
The Board has announced several significant leadership appointments to support its strategic direction. Dr. Anuj Goel has been designated as Chief Development Officer, and Mr. Susheel Umesh has been named Chief Commercial Officer – Emerging Markets, both effective immediately. Additionally, to strengthen its governance post-integration, the company will appoint a new slate of independent directors, including Mr. Rajiv Malik, Mr. Daniel Bradbury, Mr. Peter Baron Piot, Mr. Arun Suresh Chandavarkar, and Ms. Nivruti Rai, effective August 01, 2026.
Auditor Transition and Incentive Plans
In a major governance shift, the Board has recommended the appointment of M/s. S. R. Batliboi & Associates LLP as the new Statutory Auditors for a five-year term, starting from the conclusion of the 48th Annual General Meeting, replacing the retiring firm M/s. B S R & Co. LLP. Furthermore, the company has introduced the Biocon Unity Long Term Incentive Plan 2026, an equity-based incentive scheme for eligible employees designed to drive long-term value creation.
Source: BSE
